|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
12
|
|
pubmed:dateCreated |
2007-6-7
|
|
pubmed:abstractText |
Extracellular signal-regulated kinase-1/2 (ERK1/2) is frequently found constitutively activated (p-ERK1/2) in hematopoietic diseases, suggesting a role in leukemogenesis. The aim of this study was to assess the expression and clinical role of p-ERK1/2 in adult acute lymphoblastic leukemia (ALL). In 131 primary samples from adult de novo ALL patients enrolled in the Gruppo Italiano per le Malattie Ematologiche dell'Adulto (GIMEMA) Leucemia Acute Linfoide (LAL) 2000 protocol and evaluated by flow cytometry, constitutive ERK1/2 activation was found in 34.5% of cases; these results were significantly associated with higher white blood cell (WBC) values (P=.013). In a multivariate analysis, p-ERK1/2 expression was an independent predictor of complete remission achievement (P=.027). Effective approaches toward MEK inhibition need to be explored in order to evaluate whether this may represent a new therapeutic strategy for adult ALL patients.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
0006-4971
|
|
pubmed:author |
pubmed-author:AndreeffMichaelM,
pubmed-author:AnninoLucianaL,
pubmed-author:CameraAndreaA,
pubmed-author:CantoreNicolaN,
pubmed-author:CiminoGiuseppeG,
pubmed-author:De CaveFabianaF,
pubmed-author:Di RaimondoFrancescoF,
pubmed-author:FabbianoFrancescoF,
pubmed-author:FaziPaolaP,
pubmed-author:FioritoniGiuseppeG,
pubmed-author:FoàRobinR,
pubmed-author:GIMEMA Acute Leukemia Working Party,
pubmed-author:GregorjChiaraC,
pubmed-author:LuppiMarioM,
pubmed-author:ManciniMarcoM,
pubmed-author:MandelliFrancoF,
pubmed-author:MeloniGiovannaG,
pubmed-author:MilellaMicheleM,
pubmed-author:MiragliaEustachioE,
pubmed-author:MosnaFedericoF,
pubmed-author:PalmieriSalvatoreS,
pubmed-author:PetrucciMaria TMT,
pubmed-author:RicciardiMaria RMR,
pubmed-author:RoncoFrancescaF,
pubmed-author:ScerpaMaria CMC,
pubmed-author:SpecchiaGiorginaG,
pubmed-author:TafuriAgostinoA,
pubmed-author:VignettiMarcoM,
pubmed-author:VitaleAntonellaA
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
109
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
5473-6
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:17351113-Adolescent,
pubmed-meshheading:17351113-Adult,
pubmed-meshheading:17351113-Female,
pubmed-meshheading:17351113-Flow Cytometry,
pubmed-meshheading:17351113-Humans,
pubmed-meshheading:17351113-Leukocytes,
pubmed-meshheading:17351113-Male,
pubmed-meshheading:17351113-Middle Aged,
pubmed-meshheading:17351113-Mitogen-Activated Protein Kinase 1,
pubmed-meshheading:17351113-Mitogen-Activated Protein Kinase 3,
pubmed-meshheading:17351113-Phosphorylation,
pubmed-meshheading:17351113-Precursor Cell Lymphoblastic Leukemia-Lymphoma,
pubmed-meshheading:17351113-Predictive Value of Tests,
pubmed-meshheading:17351113-Prognosis,
pubmed-meshheading:17351113-Remission Induction
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
ERK1/2 phosphorylation is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia.
|
|
pubmed:affiliation |
Division of Hematology, Department of Cellular Biotechnologies and Hematology, University La Sapienza of Rome, Italy.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
